The evolving clinical profile of abatacept (CTLA4-lg): A novel co-stimulatory modulator for the treatment of rheumatoid arthritis

Arthritis Research and Therapy

Volumn 7, Issue SUPPL. 2, 2005, Pages

  Ruderman, Eric M ^a   Pope, Richard M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; B7 ANTIGEN; BELATACEPT; CD28 ANTIGEN; CD86 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; HYBRID PROTEIN; METHOTREXATE; PLACEBO; RECOMBINANT CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 FC FUSION PROTEIN; UNCLASSIFIED DRUG;

ANXIETY DISORDER; BREAST CANCER; CELLULITIS; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MOLECULAR MECHANICS; NONHUMAN; PILOT STUDY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FC FRAGMENTS; LYMPHOCYTE ACTIVATION; MALE; MICE; MIDDLE AGED; MULTICENTER STUDIES; PILOT PROJECTS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 21644468434     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1688     Document Type: Review

References (27)

1. Keystone EC: Abandoned therapies and unpublished trials in rheumatoid arthritis. Curr Opin Rheumatol 2003, 15:253-258.
2. Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, et al.: Costimulatory blockade in patients with rheumatoid arthritis: a pilot dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002, 46:1470-1479.
3. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915.
4. Jenkins MK, Taylor PS, Norton SD, Urdahl KB: CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991, 147:2461-2466.
5. Salomon B, Bluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001, 19:225-252.
6. Verwilghen J, Lovis R, De Boer M, Linsley PS, Haines GK, Koch AE, Pope RM: Expression of functional B7 and CTLA4 on rheumatoid synovial T cells. J Immunol 1994, 153:1378-1385.
7. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA: CTLA-4: a negative regulator of autoimmune disease. J Exp Med 1996, 184:783-788.
8. Walunas TL, Bakker CY, Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996, 183:2541-2550.
9. Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA: Cutting Edge: CD28 controls peripheral homeostasis of CD4+, CD25+ Regulatory T cells. J Immunol 2003, 171:3348-3352.
10. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991, 174:561-569.
11. Walunas TL, Bluestone JA: CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol 1998, 160: 3855-3860.
12. Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA4Ig. Science 1994, 265:1225-1227.
13. Perrin PJ, Scott D, Quigley L, Albert PS, Feder O, Gray GS, Abe R, June CH, Racke MK: Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J Immunol 1995, 154:1481-1490.
14. Cross AH, Girard TJ, Giacoletto KS, Evans RJ, Keeling RM, Lin RF, Trotter JL, Karr RW: Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest 1995, 95: 2783-2789.
15. Girvin AM, Dal Canto MC, Rhee L, Salomon B, Sharpe A, Bluestone JA, Miller SD: A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J Immunol 2000, 164:136-143.
16. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ: Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 1995, 96:987-993.
17. Daikh DI, Wofsy D: Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001, 166:2913-2916.
18. Tada Y, Nagasawa K, Ho A, Morito F, Ushiyama O, Suzuki N, Ohta H, Mak TW: CD28-deficient mice are highly resistant to collagen-induced arthritis. J Immunol 1999, 162:203-208.
19. - T cells in patients with rheumatoid arthritis. Arthritis Res Ther 2003, 5: R210-R213.
20. Weinblatt M, Schiff M, Goldman M, Kremer J, Breazna A, Becker JC. A pilot multi-center, randomized, double-blind, placebo controlled [study] of a co-stimulation blocker CTLA4Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis [abstract]. Arthritis Rheum 2002, Suppl:S204.
21. Emery P, Russell A, Kremer J, Williams GR, Li T, Nuamah I, Becker JC, Weisman MH. Improvement in health-related quality of life with treatment of CTLA4Ig (BMS-188667), a selective co-stimulation modulator, over one year in patients with active rheumatoid arthritis using methotrexate [abstract]. Arthritis Rheum 2003, Suppl:S4.
22. Emery P, Westhovens R, Moreland L, Nuamah I, Aranda R, Becker J, Kremer J: CTLA4Ig (BMS-188667) in a phase IIb, multicenter, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving methotrexate showed correlation between the clinical response and key biomarkers [abstract]. Presented at: European League Against Rheumatism Annual Meeting, Lisbon, Portugal 2003 http://mcic3.textor.com/cgi-bin/mc/printabs.pl?APP=eular2003SCIE- abstract&TEMPLATE=&keyf=0896&showHide=show&client=
23. Kremer J, Shergy W, Tindall E, Aranda R, Nuamah I, Zhou Y, Becker JC. Sustained clinical efficacy demonstrated by the selective co-stimulation modulator abatacept (CTLA4Ig) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract]. Arthritis Rheum 2004, Suppl:S182.
24. Dougados M, Weswthovens R, St Clair EW, Aranda R, Nuamah I, Zhou Y, Vratsanos G, Becker JC: Sustained remission and major clinical response at 2 years shown with abatacept (CTLA4Ig) in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract]. Arthritis Rheum 2004, Suppl:S185.
25. Moreland L, Weisman M, Alten R, Aranda R, Zhou Y, Wu K, Nuamah I, Becker JC: Abatacept (CTLA4Ig) in combination with methotrexate for the treatment of rheumatoid arthritis: favorable safety and tolerability profile sustained over 2 years [abstract]. Arthritis Rheum 2004, Suppl:S563.
26. Kremer J, Westhovens R, Moreland L, Emery P, Russell A, Ge Z, Aranda R, Becker JC: Efficacy and safety of the selective costimulation modulator abatacept with methotrexate for treating rheumatoid arthritis: 1-year clinical and radiographic results from the phase III AIM (Abatacept in INadequate responders to Methotrexate) trial [abstract]. Presented at: American College of Rheumatology Annual Scientific Meeting, San Antonio, TX 2004 [http://www.abstractsonline.com/viewer/viewAbstract.asp?CKey= {85C06A69-418B-47A1-BEF0-F919C8C4F640}&MKey= {6A95EDC3-27BB-49C8-9CE4-3C06FC50D63E}&AKey= {AA45DD66-F113-4CDD-8E62-01A05F613C0D}&SKey= {8FF4FA39-962F-41CF-B617-5E132EB117E5}.
27. Genovese MC, Luggen M, Schiff M, Sherrer Y, Nuamah I, Aranda R, Becker JC, Dougados M: Efficacy and safety of abatacept (CTLA4Ig), a selective co-stimulation modulator, in rheumatoid arthritis patients not responding adequately to anti-TNF-a[ED:alpha] therapy: results of the phase III ATTAIN (Abatacept Trial in Treatment of Anti-TNF Inadequate responders) trial [abstract]. Presented at: American College of Rheumatology Annual Scientific Meeting, San Antonio, TX 2004 [http://www.abstractsonline.com/viewer/viewAbstract.asp?CKey= {460C7526-77D4-4A49-AD2D-440A2515EE22}&MKey= {6A95EDC3-27BB-49C8-9CE4-3C06FC50D63E}&AKey= {AA45DD66-F113-4CDD-8E62-01A05F613C0D}&SKey= {100FBD25-6760-48B9-A4F5-EEEE63E1DAAA}.